Company
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
746 stories · page 15 of 38
"Sotrovimab is the first monoclonal antibody to report preclinical data demonstrating activity against all tested SARS-CoV-2 variants of concern and interest to date, including omicron, as well as the still prevalent and highly contagious d
Sotrovimab was deliberately designed with a mutating virus in mind
Berenberg price target is 1,630p and 'buy' its investment view
Earnings in 2021 are now expected to decline by between 2% to 4%, compared to a predicted fall of mid to high-single-digits
Wetherspoons and Mitchells & Butlers were among the best risers
Archive
GlaxoSmithKline is scheduled to publish a quarterly update, however it may only get attention from activist investors Elliott Management and Bluebell Capital Partners
Elliott Management and Bluebell Capital Partners will closely watch any statement from the chief executive
Activist Elliott has already called for the consumer unit to be sold
GSK House was opened by Tony Blair in 2002 after the merger of SmithKline Beecham and GlaxoWellcome.
Flu deaths could reach 60,000 this winter, a report from the Academy of Medical Sciences found
Only eight women are chief executives and 15 chief financial officers or finance directors at the biggest companies listed in London
RTS,S vaccine, in combination with seasonal administration of antimalarials, lowers clinical episodes of malaria, hospital admissions with severe malaria and deaths by around 70%, the company said.
In human studies are expected of the new medicine are expected to start in 2023
Both activists are pushing for the drug giant to launch a new process to find a boss for the drug and vaccine business once the consumer health arm is spun off
Jefferies International is a fan of the drug developer
This study will be one of the first global Phase 3 trials to compare two different Covid-19 vaccine candidates
The European broker sees around 8% upside to for the pharma giant.
GSK is one of several companies - most of them headed by women, coincidentally (?) - to come under pressure from activist investors
The pharma needs to show some earnings growth rather than just be seen as a value stock
Sales of Shingles vaccine Shingrix are recovering more slowly than expected
